Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abraxane Drives Growth In Potential $1bn Pancreatic Cancer Market

This article was originally published in Scrip

Executive Summary

The year-on-year growth rate of pancreatic cancer drug sales will be around 10% until peaking at around $1bn in 2023. The growth will be driven primarily by strong uptake of Celgene's Abraxane (nab-paclitaxel albumin bond) for the treatment of advanced pancreatic cancer, according to a recent forecast by Datamonitor Healthcare.


Related Content

Biomarkers For Pancreatic Cancer To Be Tested In Multi-drug Collaborative Study
NewLink’s HyperAcute Program In Limbo After Pancreatic Trial Blow-Up





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts